Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q1 2024 · 10-Q
Revenue$177.00K$177.00K−42.9% vs Q1 2023 Net Income-$6.90M-$6.90MN/M vs Q1 2023 EPS Diluted-$0.94-$0.94no prior Q1 2023 on file Operating Income-$6,998,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
Margins · derivedOperating margin-3953.7%+2422.7 pt vs Q1 2023
Net margin-3900.0%+2477.4 pt vs Q1 2023
ended Jun 30, 2023 · filed Aug 10, 2023 · 41 d after period end